Background: Patients affected by pre-existing chronic spontaneous/Inducible urticaria (CSU/CIU) still feel unsafe due to the potential risk of an Adverse Event Following Immunization (AEFI) and Cutaneous Adverse Reactions (CARs) of COVID-19 vaccines. The appropriate management in this field remains debated and evidence is still lacking. Methods: We considered 160 CSU/CIU patients in Omalizumab/antihistamine therapy who received two doses of Comirnaty/Moderna mRNA vaccines; 20 of them also received a booster dose. Urticaria Activity Score-7 (UAS7) was used to assess the severity of the disease. Demographics, medical history, AEFI and CARs outcome after vaccination were collected by administering a web-based questionnaire completed by phone interview. Results: In total, 147 patients did not show urticaria relapse (91.88%). Worsening cutaneous symptoms were experienced by 13 of our patients (8.12%). Exacerbation had a mean duration of 2 days and 11 h and mostly occurred after the first dose (69.23%). Systemic mild side effects were experienced by 9 patients (5.62%). No severe reactions were observed. Conclusions: Omalizumab can potentially prevent CARs and AEFI; however, major problems were registered during the 2-month stop period scheduled in the treatment. We suggest patients should not undergo vaccination during this period. CSU/CIU exacerbations appear to be transient and can be managed by antihistamines.

Cutaneous aging is characterized by gradual structural and functional alterations, including collagen breakdown and reduced elasticity. In recent years, several energy-based modalities have been introduced to address these changes. The aim of this study was to assess the effectiveness of a 675 nm laser and microfocused ultrasound (MFU), applied individually or in combination, for the treatment of facial aging. This retrospective analysis included 115 patients, allocated into three groups: Group A (675 nm laser), Group B (MFU), and Group C (combined protocol). Efficacy was evaluated through the Fitzpatrick Wrinkle Scale (FWS), the Baker Gravitational Ptosis Classification (BGP), and standardized photographic assessments at 1, 3, and 6 months following treatment. At the 6-month evaluation, individuals treated with the combined protocol exhibited a more pronounced improvement in wrinkle reduction (FWS: from 1.88 to 1.13) and laxity reduction (BGP: from 2.78 to 1.55) compared with either single-treatment group. No major side effects were observed. The combined application of the 675 nm laser and MFU appears to potentiate collagen remodeling and skin tightening more effectively than monotherapy. Further prospective studies are needed to validate these results and further clarify the molecular pathways involved.